Estradiol Gel 50gm 0.06%

Route: Topical transdermal gel.

• Apply once daily to clean, dry, intact skin on the upper arm, inner forearm, or thigh as directed by the prescriber.
• Apply the prescribed metered dose (number of pump actuations); spread over a 5–7 cm area and allow 1–2 minutes to dry before dressing.
• Rotate application sites within the prescribed region to minimize local skin reactions.
• Wash hands immediately after application.
• Avoid skin-to-skin contact with others (children, men) until gel is fully absorbed.

Dosing is identical to the 37.5 g presentation — prescriber-directed based on symptom control and serum estradiol monitoring:

• Standard starting dose: 1.25 g once daily (~0.75 mg estradiol/day).
• May be adjusted up to 2.5 g/day based on clinical response; the 50 g container provides approximately 40 days at 1.25 g/day.
• Women with an intact uterus require concurrent progestogen therapy.
• Reassess estradiol levels and symptom control at 4–8 weeks after initiation or dose change.

• Estradiol (0.06% transdermal): Percutaneous absorption delivers 17β-estradiol into systemic circulation, bypassing hepatic first-pass metabolism. Estradiol binds ERα and ERβ with high affinity, mediating genomic (transcriptional) and non-genomic (rapid membrane signaling) effects. Genomic effects regulate bone density (inhibiting osteoclastogenesis), hypothalamic thermoregulation (suppressing vasomotor instability), vaginal epithelial proliferation, serotonergic/noradrenergic tone (mood and cognition), and collagen synthesis. Non-genomic effects occur via membrane-bound GPER and mERs, activating MAPK, PI3K, and eNOS pathways relevant to vascular tone.

Clinical Context: Identical therapeutic indication to Estradiol Gel 37.5gm 0.06%; the larger container size accommodates patients who prefer less-frequent refill dispensing (approximately 40 days vs. 30 days at standard dosing). Used for menopausal vasomotor symptoms, genitourinary syndrome, bone density maintenance, mood stabilization, and other estrogen-deficiency manifestations. Monitor as detailed for the 37.5 g formulation.

Monitoring:

• Serum estradiol at 4–8 weeks and with dose changes.
• Endometrial surveillance in women with intact uterus; concurrent progestogen required.
• Annual mammography; blood pressure monitoring.
• Annual clinical reassessment of HRT benefit-risk.

Contraindications:

• Estrogen-dependent malignancies (breast, endometrial).
• Undiagnosed abnormal uterine bleeding.
• Active or prior VTE, PE, or arterial thromboembolic disease.
• Known thrombophilic disorders.
• Active hepatic disease.
• Pregnancy.

Warnings & Precautions:

• Endometrial cancer risk with unopposed estrogen — progestogen required in non-hysterectomized patients.
• Breast cancer risk with prolonged use — annual mammography.
• Thromboembolic risk — transdermal route avoids hepatic first-pass procoagulant effects but is not risk-free.
• Transfer risk — wash hands, allow drying before contact.

Drug Interactions:

• CYP3A4 inducers (rifampin): reduce estradiol levels.
• CYP3A4 inhibitors (ketoconazole): increase estradiol exposure.
• Thyroid hormone: monitor TSH/free T4.

Common Side Effects: Breast tenderness, headache, nausea, application site reactions, bloating, breakthrough spotting, mood changes.

Store at controlled room temperature (20–25°C / 68–77°F). Do not freeze. Protect from light and heat. Keep pump tightly capped. Store out of reach of children and away from household members who should not be exposed to estrogen. Use before the beyond-use date assigned by Genesis Compounding.

Why is this 50g vs the 37.5g container?

The 50g container provides a larger supply — approximately 40 days at the standard 1.25 g/day dose versus approximately 30 days for 37.5 g — reducing refill frequency. The formulation concentration (0.06%) and dosing are identical; the prescriber selects the container size based on patient preference and dispensing interval.

Is the concentration the same as the smaller container?

Yes — both 37.5 g and 50 g containers are 0.06% estradiol (0.6 mg/g). The estradiol content per pump actuation is identical; only the total supply volume differs.

Do I need to use progestogen with this gel?

If you have an intact uterus, concurrent progestogen is required to protect the endometrium. Women who have had a hysterectomy typically do not require progestogen supplementation. The prescriber makes this determination based on individual anatomy and history.

How should I apply the gel correctly?

Apply to clean, dry skin (upper arm, inner forearm, or thigh). Use the number of pump actuations specified by your prescriber. Spread gently over a small area; do not rub vigorously. Allow 1–2 minutes to dry. Wash hands after application. Do not apply to breasts or irritated skin.

Is this product FDA-approved?

An FDA-approved 0.06% estradiol topical gel (EstroGel®) exists for menopausal vasomotor symptoms. This compounded 50 g preparation is a patient-specific 503A preparation from Genesis Compounding prepared under prescriber direction and is not itself FDA-approved as a compounded product.